Rating Change
Goldman Sachs reiterated its Neutral rating on Moderna, Inc. (NASDAQ:MRNA) on August 20, 2026.
reiterateNASDAQ:MRNA
Goldman Sachs Reiterates Neutral Rating on Moderna, Inc. (MRNA)
Goldman Sachs reiterated its Neutral rating on Moderna, Inc. (NASDAQ:MRNA) on August 20, 2026.
At publication ·
What changed
Moderna, Inc. (NASDAQ:MRNA) · reiterate
- Firm
- Goldman Sachs
- Rating
- Neutral to Neutral
- Price at event
- $133.32
- Market capitalization
- $11.6B
At a glance
Key takeaways
- Goldman Sachs reiterated a Neutral rating on Moderna (MRNA) on August 20, 2026, with the stock trading at $133.32 and a market capitalization of $11.6 billion.
Market Context
Moderna, Inc. operates in the Healthcare sector. The stock currently trades at $133.32 with a market capitalization of $11.6B. The stock has gained 413.2% over the past 52 weeks.
Analyst coverage from Goldman Sachs provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Moderna, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Moderna, Inc.
Among the 10 most recent ratings: 2 Buy, 7 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 20, 2026 | UBS | Neutral | N/A |
| Aug 20, 2026 | Goldman Sachs | Neutral | N/A |
| Aug 20, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Aug 19, 2026 | William Blair | Outperform | N/A |
| Aug 03, 2026 | Citigroup | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View MRNA Stock Page
Frequently Asked Questions
What does the Neutral rating mean for MRNA?
A rating of Neutral from Goldman Sachs reflects the analyst's outlook on Moderna, Inc. (NASDAQ:MRNA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MRNA forecast page.
